Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$437K Buy
3,381
+94
+3% +$11.4K 0.02% 350
2025
Q1
$393K Buy
3,287
+20
+0.6% +$2.48K 0.02% 351
2024
Q4
$379K Buy
3,267
+38
+1% +$4.8K 0.02% 364
2024
Q3
$436K Buy
3,229
+144
+5% +$19.3K 0.03% 329
2024
Q2
$418K Buy
3,085
+267
+9% +$36.3K 0.03% 316
2024
Q1
$364K Buy
2,818
+20
+0.7% +$2.42K 0.03% 339
2023
Q4
$320K Buy
+2,798
New +$279K 0.03% 345
2023
Q3
Sell
-2,027
Closed -$228K 430
2023
Q2
$228K Buy
+2,027
New +$214K 0.02% 350

Other funds holding XYL

Graypoint LLC's XYL Position: Q2 2025 in Review

Graypoint LLC increased its Xylem (XYL) stake by 2.9% in Q2 2025, buying an estimated $11.4K and bringing the position to 3,381 shares worth $437K. The position accounts for 0.02% of the portfolio, ranked #350.

Graypoint LLC first reported a position in XYL in Q2 2023 and has held it in 8 quarters since. 1,063 funds tracked by Wall St. Rank hold XYL as of Q2 2025.

  • Graypoint LLC held 3,381 shares of Xylem worth $437K as of Q2 2025.
  • Graypoint LLC bought 94 Xylem shares in Q2 2025, an estimated $11.4K.
  • Xylem made up 0.02% of Graypoint LLC's portfolio in Q2 2025, its #350 holding.
  • Graypoint LLC first reported a position in Xylem in Q2 2023 and has held it in 8 quarters since.
  • 1,063 funds tracked by Wall St. Rank held Xylem as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.